The impact of oral anticoagulant therapy, factor VIII level and quality of factor V-deficient plasma on three commercial methods for activated protein C resistance - Chitolie, A; Lawrie, AS; Mackie, IJ (Blood Coagul Fibrinolysis, 2001)
et al.